首页> 外文期刊>Journal of applied clinical medical physics / >Comprehensive validation of halcyon 2.0 plans and the implementation of patient specific QA with multiple detector platforms
【24h】

Comprehensive validation of halcyon 2.0 plans and the implementation of patient specific QA with multiple detector platforms

机译:Halcyon 2.0计划的综合验证和具有多个探测器平台的患者特定QA的实施

获取原文
           

摘要

Purpose To perform a comprehensive validation of plans generated on a preconfigured Halcyon 2.0 with preloaded beam model, including evaluations of new features and implementing the patient specific quality assurance (PSQA) process with multiple detectors. Methods A total of 56 plans were generated in Eclipse V15.6 (Varian Medical System) with a preconfigured Halcyon treatment machine. Ten plans were developed via the AAPM TG‐119 test suite with both IMRT and VMAT techniques. 34 clinically treated plans using C‐arm LINAC from 24 patients were replanned on Halcyon using IMRT or VMAT techniques for a variety of sites including: brain, head and neck, lung, breast, abdomen, and pelvis. Six of those plans were breast VMAT plans utilizing the extended treatment field technique available with Halcyon 2.0. The dynamically flattened beam (DFB), another new feature on Halcyon 2.0, was also used for an AP/PA spine and four field box pelvis, as well as ten 3D breast plans. All 56 plans were measured with an ion chamber (IC), film, portal dosimetry (PD), ArcCHECK, and Delta4. Tolerance and action limits were calculated and compared to the recommendations of TG‐218. Results TG‐119 IC and film confidence limits met those set by the task group, except for IMRT target point dose. Forty‐four of 46 clinical plans were within 3% for IC measurements. Average gamma passing rates with 3% dose difference and 2mm distance‐to‐agreement for IMRT/VMAT plans were: Film – 96.8%, PD – 99.9%, ArcCHECK – 99.1%, and Delta4 – 99.2%. Calculated action limits were: Film – 86.3%, PD – 98.4%, ArcCHECK – 96.1%, and Delta4 – 95.7%. Extended treatment field technique was fully validated and 3D plans with DFB had similar results to IMRT/VMAT plans. Conclusion Halcyon plan deliveries were verified with multiple measurement devices. New features of Halcyon 2.0 were also validated. Traditional PSQA techniques and process specific tolerance and action limits were successfully implemented.
机译:目的,在预配置的Halcyon 2.0上进行全面验证,具有预加载的光束模型,包括对新功能的评估,并利用多种探测器实现患者特定质量保证(PSQA)过程。方法使用预配置的菱锡处理机,共生56种计划。通过AAPM TG-119测试套件开发了十个计划,具有IMRT和VMAT技术。使用24名患者的34种临床治疗计划,使用24名患者因各种部位的IMRT或VMAT技术而重申了哈西顿,包括:脑,头部和颈部,肺,乳房,腹部和骨盆。这些计划中的六个是利用Halcyon 2.0可用的扩展处理领域技术的乳房VMAT计划。动态扁平的光束(DFB),Halcyon 2.0上的另一个新功能也用于AP / PA脊柱和四个野外盒骨盆,以及10个3D乳房计划。所有56个计划用离子室(IC),薄膜,门圈剂量法(PD),ArcCheck和Delta4测量。计算公差和行动限制,并与TG-218的建议进行比较。结果TG-119 IC和电影置信度限制满足任务组设置的,除了IMRT目标点剂量。 46个临床计划中的四十四个占IC测量的3%。平均伽玛通过率为3%的剂量差异和2mm的IMRT / VMAT计划的距离 - 达到达法的距离:薄膜 - 96.8%,PD - 99.9%,ArcCheck - 99.1%和Delta4 - 99.2%。计算的动作限制是:薄膜 - 86.3%,PD - 98.4%,ArcCheck - 96.1%,Delta4 - 95.7%。扩展处理现场技术已完全验证,DFB的3D计划与IMRT / VMAT计划相似。结论Halcyon计划用多种测量装置验证了核算。 Halcyon 2.0的新功能也得到了验证。成功实施了传统的PSQA技术和流程特定的容忍度和行动限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号